National Weekly Bulletin

Year: Week:

NATIONAL WEEKLY INFLUENZA BULLETIN OF THE RUSSIAN FEDERATION

week 3 of 2025 (13.01.25 - 19.01.25)

Summary

Influenza and ARI incidence data. Influenza and other ARI activity in Russia increased in comparison with previous week. The nationwide ILI and ARI morbidity level (52.2 per 10 000 of population) was lower than national baseline (89.9) by 41.9%.

Etiology of ILI & ARI. Among 10760 patients investigation 599 (5.6%) respiratory samples were positive for influenza, including 103 cases of unsubtyped influenza A in 11 cities, 294 cases of influenza A(H1N1)pdm09 in 43 cities, 2 cases of influenza A(H3N2) in 2 cities and 200 cases of influenza B in 24 cities.

7 influenza viruses were isolated on MDCK cell culture, including 6 cases of influenza A(H1N1)pdm09 in Astrakhan (1), Krasnodar (3), Saint-Petersburg (2) and 1 case of influenza B in Samara. Since the beginning of the season 29 influenza viruses, including: 19 A(H1N1)pdm09 viruses, 3 - A(H3N2) and 7 influenza B viruses.

Antigenic characterization. Since the beginning of the season 12 influenza have been antigenically characterized by the NICs, including: 9 influenza A(H1N1)pdm09, 1 influenza A(H3N2) and 2 influenza B viruses. 8 A(H1N1)pdm09 viruses were similar to the reference strain A/Victoria/4897/22 recommended in the vaccines for the Northern Hemisphere countries for the 2024-2025 season, one A(H1N1)pdm09 strain reacted to a 1:8 homologous titer with serum to the vaccine strain. One A(H3N2) strain interacted to 1:8 homologous titer with serum to vaccine strain A/Thailand/8/22. Influenza B viruses were similar to vaccine strain B/Austria/1359417/2021.  

Genetic analysis. Since the beginning of the season 2023-2024, sequencing of 6 A(H1N1)pdm09 influenza isolates, 1779 influenza viruses and isolates from primary clinical materials from patients and 50 B influenza isolates were performed. According to phylogenetic analysis, 6 A(H1N1)pdm09 influenza isolates were assigned to genetic clade 6B.1A.5a.2a and similar to the vaccine strain A/Victoria/2570/2019, 1762 influenza A(H3N2) viruses were assigned to genetic clade 3C.2a1b.2a.2а.3а.1 and similar to the reference strain A/Thailand/08/2022, 16 viruses were assigned to genetic clade 2a.3b and similar to the reference virus A/Sydney/732/2022 and 1 strain - assigned to clade 3C.2a.1b.2a.2a.2a.3b and similar to the reference virus A/Sydney/732/2022. 50 B influenza isolates were assigned to genetic subclade V1A.3a.2 and similar to the vaccine strain B/Austria/1359417/2021. All viruses were sensitive to neuraminidase inhibitors (oseltamivir, zanamivir).

Susceptibility to antivirals. Since the beginning of the season 2024-2025, the sensitivity of 7 influenza viruses to neuraminidase inhibitors (oseltamivir, zanamivir) was studied in NIC Saint-Petersburg, including: 3 A(H1N1)pdm09 influenza viruses, 1 A(H3N2) influenza virus and 3 influenza B viruses. All studied viruses were sensitive to neuraminidase inhibitors.

ARVI detections. The overall proportion of respiratory samples tested positive for other ARVI (PIV, ADV, RSV, RhV, CoV, MPV, BoV) was estimated in total as 11.2% (PCR).

In sentinel surveillance system clinical samples from 42 SARI patients were investigated by rRT-PCR for influenza, among them 1 (2.4%) case of influenza A(H1N1)pdm09 was recognized. Among 42 SARI patients no positive cases of coronavirus SARS-CoV-2 recognized. Among 42 SARI samples 10 (23.8%) cases positive for ARVI were detected including: 1 case of PIV, 1 case of ADV, 6 cases of CoV and 2 cases of MPV infection.

Clinical samples from 30 ILI/ARI patients were investigated by rRT-PCR for influenza, among them 3 (10.0%) case of influenza B were recognized. Among 18 ILI/ARI samples 5 (27.8%) cases positive for ARVI detected, including: 1 case of PIV, 2 cases of RhV, 1 case of CoV and 1 case of MPV infection. Among 30 ILI/ARI patients no positive cases of coronavirus SARS-CoV-2 recognized.

COVID-19. Totally 24 877 276 cases and 404 314 deaths associated with COVID-19 were registered in Russia including 10 025 cases and 43 deaths in week 03. According to the data obtained by NIC in Saint-Petersburg totally 11011 clinical samples were PCR investigated in last week. Among them coronavirus SARS-CoV-2 detected in 288 (2.6%) cases.

Influenza and ARI morbidity data

Fig. 1. Influenza and ARVI morbidity in 61 cities under surveillance in Russia, seasons 2023/24 and 2024/25
Rates per 10 000 populationFig. 1. Influenza and ARVI morbidity in 61 cities under surveillance in Russia, seasons 2023/24 and 2024/25

Weeks

  • Morbidity 2024/25Morbidity 2024/25
  • Morbidity 2023/24Morbidity 2023/24
  • MEM baseline 2024/25MEM baseline 2024/25

Epidemiological data showed increase of influenza and other ARI activity in Russia in comparison with previous week. The nationwide ILI and ARI morbidity level (52.2 per 10 000 of population) was lower than national baseline (89.9) by 41.9%.

Fig. 2. Comparative data on incidence rate of clinically diagnosed influenza, seasons 2023/24 and 2024/25
Rates per 10 000 populationFig. 2. Comparative data on incidence rate of clinically diagnosed influenza, seasons 2023/24 and 2024/25

Weeks

  • Season 2024/25Season 2024/25
  • Season 2023/24Season 2023/24
  • MEM baselineMEM baseline

Incidence rate of clinically diagnosed influenza increased comparing to previous week and amounted to 0.6 per 10 000 of population, it was higher than pre-epidemic MEM baseline (0.040).

Fig. 3. Comparison of hospitalization rate with clinical diagnosis of influenza, seasons 2023/24 and 2024/25
Rates per 10 000 populationFig. 3. Comparison of hospitalization rate with clinical diagnosis of influenza, seasons 2023/24 and 2024/25

Weeks

  • Season 2024/25Season 2024/25
  • Season 2023/24Season 2023/24
  • MEM baselineMEM baseline

Hospitalization rate of clinically diagnosed influenza increased comparing to previous week and amounted to 0.14 per 10 000 of population, it was higher than pre-epidemic MEM baseline (0.010).

Influenza and ARVI laboratory testing results

Cumulative results of influenza laboratory diagnosis by rRT-PCR were submitted by 49 RBLs and two WHO NICs. According to these data as a result of 10760 patients investigation 599 (5.6%) respiratory samples were positive for influenza, including 103 cases of unsubtyped influenza A in 11 cities, 294 cases of influenza A(H1N1)pdm09 in 43 cities, 2 cases of influenza A(H3N2) in 2 cities and 200 cases of influenza B in 24 cities.

7 influenza viruses were isolated on MDCK cell culture, including 6 cases of influenza A(H1N1)pdm09 in Astrakhan (1), Krasnodar (3), Saint-Petersburg (2) and 1 case of influenza B in Samara. Since the beginning of the season 29 influenza viruses, including: 19 A(H1N1)pdm09 viruses, 3 - A(H3N2) and 7 influenza B viruses.

Antigenic characterization. Since the beginning of the season 12 influenza have been antigenically characterized by the NICs, including: 9 influenza A(H1N1)pdm09, 1 influenza A(H3N2) and 2 influenza B viruses. 8 A(H1N1)pdm09 viruses were similar to the reference strain A/Victoria/4897/22 recommended in the vaccines for the Northern Hemisphere countries for the 2024-2025 season, one A(H1N1)pdm09 strain reacted to a 1:8 homologous titer with serum to the vaccine strain. One A(H3N2) strain interacted to 1:8 homologous titer with serum to vaccine strain A/Thailand/8/22. Influenza B viruses were similar to vaccine strain B/Austria/1359417/2021.

Genetic analysis. Since the beginning of the season 2023-2024, sequencing of 6 A(H1N1)pdm09 influenza isolates, 1779 influenza viruses and isolates from primary clinical materials from patients and 50 B influenza isolates were performed. According to phylogenetic analysis, 6 A(H1N1)pdm09 influenza isolates were assigned to genetic clade 6B.1A.5a.2a and similar to the vaccine strain A/Victoria/2570/2019, 1762 influenza A(H3N2) viruses were assigned to genetic clade 3C.2a1b.2a.2а.3а.1 and similar to the reference strain A/Thailand/08/2022, 16 viruses were assigned to genetic clade 2a.3b and similar to the reference virus A/Sydney/732/2022 and 1 strain - assigned to clade 3C.2a.1b.2a.2a.2a.3b and similar to the reference virus A/Sydney/732/2022. 50 B influenza isolates were assigned to genetic subclade V1A.3a.2 and similar to the vaccine strain B/Austria/1359417/2021. All viruses were sensitive to neuraminidase inhibitors (oseltamivir, zanamivir).

Susceptibility to antivirals. Since the beginning of the season 2024-2025, the sensitivity of 7 influenza viruses to neuraminidase inhibitors (oseltamivir, zanamivir) was studied in NIC Saint-Petersburg, including: 3 A(H1N1)pdm09 influenza viruses, 1 A(H3N2) influenza virus and 3 influenza B viruses. All studied viruses were sensitive to neuraminidase inhibitors.

Fig. 4. Geographic distribution of RT-PCR detected influenza viruses in cities under surveillance in Russia, week 3 of 2025
Fig. 4. Geographic distribution of RT-PCR detected influenza viruses in cities under surveillance in Russia, week 3 of 2025
PCR results
  • No dataNo data
  • No viruses detectedNo viruses detected
  • H1pdm09H1pdm09
  • H3H3
  • H3+H1pdm09H3+H1pdm09
  • BB
  • B+H1pdm09B+H1pdm09
  • B+H3B+H3
  • B+H3+H1pdm09B+H3+H1pdm09
  • A (not subt.)A (not subt.)
  • A (not subt.)+H1pdm09A (not subt.)+H1pdm09
  • A (not subt.)+H3A (not subt.)+H3
  • A (not subt.)+H3+H1pdm09A (not subt.)+H3+H1pdm09
  • A (not subt.)+BA (not subt.)+B
  • A (not subt.)+B+H1pdm09A (not subt.)+B+H1pdm09
  • A (not subt.)+B+H3A (not subt.)+B+H3
  • A (not subt.)+B+H3+H1pdm09A (not subt.)+B+H3+H1pdm09
Fig. 5. Monitoring of influenza viruses detection by RT-PCR in Russia, season 2024/25
Number of positive casesFig. 5. Monitoring of influenza viruses detection by RT-PCR in Russia, season 2024/25% positive

Weeks

  • H1pdm09H1pdm09
  • H3H3
  • BB
  • A (not subt.)A (not subt.)
  • % positive% positive
Fig. 6. Monitoring of ARVI detection by RT-PCR in Russia, season 2024/25
Number of positive casesFig. 6. Monitoring of ARVI detection by RT-PCR in Russia, season 2024/25

Weeks

  • PIVPIV
  • ADVADV
  • RSVRSV
  • RhVRhV
  • CoVCoV
  • MPVMPV
  • BoVBoV

ARVI detections. The overall proportion of respiratory samples tested positive for other ARVI (PIV, ADV, RSV, RhV, CoV, MPV, BoV) estimated as 11.2% of investigated samples by PCR.

Fig. 7. Monitoring of influenza viruses isolation in Russia, season 2024/25
Number of positive casesFig. 7. Monitoring of influenza viruses isolation in Russia, season 2024/25% positive

Weeks

  • H1pdm09H1pdm09
  • H3H3
  • BB
  • % positive% positive

Table 1. Results of influenza and other ARVI detection by RT-PCR in Russia, week 3 of 2025

  Number of  specimens / number of positive cases  % positive
Influenza
Number of specimens tested for influenza 10760 -
Influenza A (not subt.) 103 1,0%
Influenza A(H1)pdm09 294 2,7% 
Influenza A(H3) 2 0,02% 
Influenza B 200 1,9% 
All influenza 599 5,6%
Other ARVI
Number of specimens tested for ARVI 10672  -
PIV 81 0,8%
ADV 132 1,2%
RSV 157 1,5%
RhV 361 3,4%
CoV 351 3,3%
MPV 32 0,3%
BoV 77 0,7%
All ARVI 1191 11,2%
SARS-CoV-2 (COVID-19)
Number of specimens tested for SARS-CoV-2 11011 -
SARS-CoV-2 288 2,6%
Fig. 8. Results of PCR detections of SARS-CoV-2 in Russia
Fig. 8. Results of PCR detections of SARS-CoV-2 in Russia
% positive
  • No dataNo data
  • less then 10%less then 10%
  • 10-20%10-20%
  • 20-30%20-30%
  • 30-40%30-40%
  • 40-50%40-50%
  • 50% and more50% and more

COVID-19. Totally 24 877 276 cases and 404 314 deaths associated with COVID-19 were registered in Russia including 10 025 cases and 43 deaths in week 03. According to the data obtained by NIC in Saint-Petersburg totally 11011 clinical samples were PCR investigated in last week. Among them coronavirus SARS-CoV-2 detected in 288 (2.6%) cases.

Table 2. Results of influenza viruses isolation in Russia, week 3 of 2025

  Number of specimens / number of viruses  % isolated viruses
Number of specimens 121 -
Influenza A(H1)pdm09 7 5,8% 
Influenza A(H3) 0 0,0% 
Influenza B 3 2,5% 
All influenza 10 8,3%

Sentinel influenza surveillance

Clinical samples from 42 SARI patients were investigated by rRT-PCR for influenza, among them 1 (2.4%) case of influenza A(H1N1)pdm09 was recognized. Among 42 SARI patients no positive cases of coronavirus SARS-CoV-2 recognized. Among 42 SARI samples 10 (23.8%) cases positive for ARVI were detected including: 1 case of PIV, 1 case of ADV, 6 cases of CoV and 2 cases of MPV infection.

Clinical samples from 30 ILI/ARI patients were investigated by rRT-PCR for influenza, among them 3 (10.0%) case of influenza B were recognized. Among 18 ILI/ARI samples 5 (27.8%) cases positive for ARVI detected, including: 1 case of PIV, 2 cases of RhV, 1 case of CoV and 1 case of MPV infection. Among 30 ILI/ARI patients no positive cases of coronavirus SARS-CoV-2 recognized.

Fig. 9. Monitoring of influenza viruses detection by RT-PCR among SARI patients in sentinel hospitals, season 2024/25
Number of positive casesFig. 9.  Monitoring of influenza viruses detection by RT-PCR among SARI patients in sentinel hospitals, season 2024/25% positive

Weeks

  • H1pdm09H1pdm09
  • H3H3
  • BB
  • A (not subt.)A (not subt.)
  • % positive% positive
Fig. 10. Monitoring of influenza viruses detection by RT-PCR among ILI/ARI patients in sentinel polyclinics, season 2024/25
Number of positive casesFig. 10.  Monitoring of influenza viruses detection by RT-PCR among ILI/ARI patients in sentinel polyclinics, season 2024/25% positive

Weeks

  • H1pdm09H1pdm09
  • H3H3
  • BB
  • A (not subt.)A (not subt.)
  • % positive% positive
Fig. 11. Monitoring of ARVI detection by RT-PCR among SARI patients in sentinel hospitals, season 2024/25
Number of positive casesFig. 11.  Monitoring of ARVI detection by RT-PCR among SARI patients in sentinel hospitals, season 2024/25

Weeks

  • PIVPIV
  • ADVADV
  • RSVRSV
  • RhVRhV
  • CoVCoV
  • MPVMPV
  • BoVBoV
Fig. 12. Monitoring of ARVI detection by RT-PCR among ILI/ARI patients in sentinel polyclinics, season 2024/25
Number of positive casesFig. 12.  Monitoring of ARVI detection by RT-PCR among ILI/ARI patients in sentinel polyclinics, season 2024/25

Weeks

  • PIVPIV
  • ADVADV
  • RSVRSV
  • RhVRhV
  • CoVCoV
  • MPVMPV
  • BoVBoV
Download PDF version